1. INTRODUCTION
===============

Non-Hodgkin lymphomas ([nhl]{.smallcaps}s) constitute a heterogeneous group of malignancies with variable presentations that range from indolent to aggressive [@b1-co16-5-32]. Patients with follicular and other indolent lymphomas can sustain prolonged remission periods, but they eventually relapse and require subsequent courses of therapy that lead to fewer and shorter remissions [@b2-co16-5-32]. Novel treatment options are necessary to improve the natural history of this condition. Rituximab is a chimeric monoclonal antibody directed against the CD20 surface antigen found on most B-cell lymphomas [@b3-co16-5-32]. Although rituximab represents an important advance in indolent disease because of its efficacy, short duration of therapy, and acceptable toxicity profile [@b4-co16-5-32], relapse remains inevitable. Therapies that are more effective are thus needed for patients who are refractory to or who relapse after currently available treatments, including rituximab.

Radioimmunoconjugates are monoclonal antibodies bound to radioisotopes, and this emerging class of agents has activity in lymphoma. These agents allow for the delivery of targeted radiation therapy with the binding of the monoclonal antibody to antigens on the surface of malignant cells. ^131^I--Tositumomab (Bexxar: Corixa Corporation, South San Francisco, CA, and GlaxoSmithKline, Philadelphia, PA, U.S.A.) is a radioimmunoconjugate consisting of an anti-CD20 murine monoclonal antibody (tositumomab) covalently bound to the gamma-emitting radioactive isotope ^131^I [@b5-co16-5-32],[@b6-co16-5-32]. Initial studies have reported on the use of ^131^I--tositumomab in patients with refractory or relapsed low-grade, follicular, or transformed lymphoma. Further research is exploring the role of this compound in other settings, including in patients with aggressive-histology lymphomas and in the setting of stem-cell transplantation. However, the routine adoption of this agent is tempered by concerns about increased costs, complex dosimetry requirements, and possible toxicities. With the recent availability of radioimmunoconjugates, a careful review of the risks and benefits of such therapy is warranted. The aim of the present systematic review is to address the following questions in patients with lymphoma of any type or stage:

-   What are the benefits associated with treatment with ^131^I--tositumomab?

-   What are the toxicities associated with the use of ^131^I--tositumomab?

-   Which patients are more or less likely to benefit from treatment with ^131^I--tositumomab?

-   Is imaging or dosimetry required for therapy to be safe and effective?

2. MATERIALS AND METHODS
========================

The methodology guiding this systematic review was developed by the Cancer Care Ontario ([cco]{.smallcaps}) Program in Evidence-Based Care ([pebc]{.smallcaps}) according to the practice guidelines development cycle [@b7-co16-5-32]. Members of the [pebc]{.smallcaps} Hematology Disease Site Group ([dsg]{.smallcaps}) selected, reviewed, and interpreted the evidence. The Hematology [dsg]{.smallcaps} has 25 members, including hematologists, medical and radiation oncologists, an epidemiologist, and two lay representatives.

2.1 Literature Search
---------------------

We searched the [medline]{.smallcaps} (1966 to July 2005), [embase]{.smallcaps} (1980 to July 2005), and Cochrane Library (2005, Issue 3) databases using the search strategy shown in [Table I](#tI-co16-5-32){ref-type="table"}. In addition, we searched the conference proceedings of the American Society of Hematology ([ash]{.smallcaps}) for 2000 to 2004 and those of the American Society of Clinical Oncology ([asco]{.smallcaps}) for 2000 to 2005. Reference lists of relevant trials and reviews were searched for additional publications. In addition, the authors searched their personal files. The Canadian Medical Association Infobase (mdm.ca/cpgsnew/cpgs/index.asp), the National Guidelines Clearinghouse ([www.guideline.gov/index.asp](www.guideline.gov/index.asp)), and the U.K. National Institute for Health and Clinical Excellence ([www.nice.org.uk/](www.nice.org.uk/)) were also searched for existing evidence-based practice guidelines.

2.2 Inclusion Criteria
----------------------

Randomized controlled trials, other comparative trials, prospective single-arm trials, systematic reviews (with or without meta-analyses), and evidence-based practice guidelines were considered for this review of the evidence if they met the following criteria:

-   Study of adult patients with lymphoma of any type, at any stage, and for any performance status

-   ^131^I--Tositumomab studied as a single agent or in combination with other regimens

-   Results reported for one or more of the following outcomes: survival, quality of life ([qol]{.smallcaps}), time to progression ([ttp]{.smallcaps}), response duration, response rate, adverse effects, tumour dosimetry or imaging

-   Report published in English

Letters, comments, and editorial publications were excluded. Conference abstracts that preceded full-paper final results were not included; however, abstracts that provided updated results or novel data were included for further data abstraction.

2.3 Data Extraction and Interpretative Summary
----------------------------------------------

Relevant articles and abstracts were selected in an unblinded manner independently by two members of the Hematology [dsg]{.smallcaps}. Data were extracted and summarized to address the following questions regarding adult patients with lymphoma of any type, at any stage, and for any performance status:

-   Is ^131^I--tositumomab effective in improving survival, [qol]{.smallcaps}, [ttp]{.smallcaps}, response duration, or response rate?

-   What are the toxicities associated with the use of ^131^I--tositumomab?

-   Which patients are more or less likely to benefit from treatment with ^131^I--tositumomab?

-   Is imaging or dosimetry required for therapy to be safe and effective?

The analysis of the data uses descriptive statistics. Categorical variables are reported as numbers and proportions, and continuous data are reported as means and standard deviations. The heterogeneity among studies precluded any pooling of results using formal meta-analytic techniques.

3. RESULTS
==========

We identified 255 citations in the literature searches of [medline]{.smallcaps}, [embase]{.smallcaps}, and the Cochrane Library, including twenty-one full publications of eleven trials. Eleven abstracts of seven trials were identified from the conference proceedings of [ash]{.smallcaps} and [asco]{.smallcaps}. One additional abstract was identified that provided [qol]{.smallcaps} data that were not reported in the relevant full publication. Only the most recent abstract or full publication was referenced for each trial, except where additional data were available in previous publications ([Table II](#tII-co16-5-32){ref-type="table"}[a](#fn2-co16-5-32){ref-type="fn"}).

In total, this systematic review includes eighteen trials investigating the use of ^131^I--tositumomab for the treatment of adult patients with [nhl]{.smallcaps}. No systematic reviews, meta-analyses, or evidence-based practice guidelines were identified. We divided the trials into two categories based on patient treatment history: previously untreated [@b25-co16-5-32],[@b27-co16-5-32],[@b29-co16-5-32],[@b31-co16-5-32],[@b35-co16-5-32] and previously treated patients with [nhl]{.smallcaps}. The "previously treated" category was further divided into randomized [@b22-co16-5-32] and single-arm trials of ^131^I--tositumomab. The single-arm trials included reports of patients with disease relapsed or refractory to chemotherapy without prior rituximab [@b5-co16-5-32],[@b8-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b19-co16-5-32],[@b28-co16-5-32]; disease relapsed or refractory to rituximab alone [@b34-co16-5-32],[@b39-co16-5-32]; disease treated with ^131^I--tositumomab conditioning for autologous stem-cell transplantation ([asct]{.smallcaps}) [@b17-co16-5-32],[@b40-co16-5-32]; and disease treated with ^131^I--tositumomab in alternative regimens or alternative populations of previously treated patients [@b23-co16-5-32],[@b32-co16-5-32].

3.1 Patients with Previously Treated NHL
========================================

3.1.1 Study Quality
-------------------

Only one of the thirteen trials of ^131^I--tositumomab in patients with previously treated [nhl]{.smallcaps} was a randomized controlled trial [@b22-co16-5-32]. That trial has been published in abstract form only, and therefore little information regarding study quality was reported. However, the authors did report that the trial was multicentred and open-label. The 78 study patients were randomized either to ^131^I--tositumomab or to unlabelled tositumomab and were followed for a median of 42.6 months. No sample-size calculation was provided.

One single-arm trial, reported as a full publication by Kaminski *et al.* [@b5-co16-5-32], compared each patient's duration of response after ^131^I--tositumomab with the duration of response to their last qualifying chemotherapy regimen ("paired control"). The remaining studies were single-arm noncomparative phase [i]{.smallcaps} or [ii]{.smallcaps} trials. Eight of those trials [@b5-co16-5-32],[@b8-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b17-co16-5-32],[@b19-co16-5-32],[@b22-co16-5-32],[@b28-co16-5-32],[@b34-co16-5-32],[@b40-co16-5-32] have been fully published, with sample sizes ranging from 11 patients to 60 patients. The remaining three trials [@b23-co16-5-32],[@b32-co16-5-32],[@b39-co16-5-32] have been published in abstract form only, with sample sizes ranging from 11 patients to 32 patients. Eight of twelve single-arm trials reported median follow-up times that ranged from 12 months [@b11-co16-5-32] to 39 months [@b34-co16-5-32].

3.1.2 Study Characteristics
---------------------------

[Table III](#tIII-co16-5-32){ref-type="table"} presents study and patient characteristics for the trials of ^131^I--tositumomab in patients with previously treated [nhl]{.smallcaps}. The randomized trial reported by Davis *et al.* [@b22-co16-5-32] included patients with CD20+ [nhl]{.smallcaps} that was relapsed or refractory (defined as progression within 1 year of treatment) to a regimen containing either an anthracycline, an anthracenedione, or an alkylating agent. Patients were randomized to either ^131^I-- tositumomab (*n* = 42) or to unlabelled tositumomab (*n* = 36). Patients who did not respond to unlabelled tositumomab could cross over to the ^131^I--tositumomab arm if they did not have a human anti-mouse antibody ([hama]{.smallcaps}) response. The authors did not report the doses given to patients in either arm. Patient characteristics were well matched between the two treatment arms.

Six of the single-arm trials enrolled patients with [nhl]{.smallcaps} that was relapsed or refractory to chemotherapy without rituximab: one phase [i]{.smallcaps} dose-escalation trial [@b8-co16-5-32], one phase [i]{.smallcaps}/[ii]{.smallcaps} dose-escalation trial [@b12-co16-5-32], and four phase [ii]{.smallcaps} trials [@b5-co16-5-32],[@b11-co16-5-32],[@b19-co16-5-32],[@b28-co16-5-32]. One of the phase [ii]{.smallcaps} trials used each patient as a self paired control for comparing the duration of response to ^131^I--tositumomab with the duration of response in the patient's last qualifying chemotherapy regimen [@b5-co16-5-32]. The phase [i]{.smallcaps} trial reported by Press *et al.* [@b8-co16-5-32] was a dose-escalation study that provided separate outcomes data for the 12 patients who received therapeutic doses of ^131^I--tositumomab. Gopal *et al.* [@b10-co16-5-32] reported a study that compared patients in sequential trials reported by Press *et al.* [@b22-co16-5-32],[@b27-co16-5-32] (treatment group, *n* = 27) with a historical control group of patients who received conventional high-dose therapy and [asct]{.smallcaps} (control group, *n* = 98).

Two single-arm phase [ii]{.smallcaps} trials enrolled patients with [nhl]{.smallcaps} relapsed or refractory to rituximab, with or without chemotherapy. The first trial, reported by Horning *et al.* [@b34-co16-5-32] included patients who were relapsed or refractory to rituximab. Nair *et al.* [@b39-co16-5-32] reported a trial that enrolled patients with CD20+ [nhl]{.smallcaps} refractory to chemotherapy and rituximab.

Two single-arm phase [i]{.smallcaps} dose escalation trials treated patients who had chemotherapy-resistant [nhl]{.smallcaps} with a regimen including ^131^I--tositumomab conditioning for [asct]{.smallcaps} [@b17-co16-5-32],[@b40-co16-5-32].

Mones *et al.* [@b32-co16-5-32] reported the results of a phase [i]{.smallcaps} trial that enrolled patients who had relapsed or refractory low-grade [nhl]{.smallcaps} and more than 25% bone marrow involvement. The first cohort of patients received ^131^I-- tositumomab at a total body dose of 45 cGy, with incremental increases of 10 cGy for subsequent cohorts.

Four of the single-arm trials reported subgroup data for patients with transformed [nhl]{.smallcaps} [@b5-co16-5-32],[@b12-co16-5-32],[@b19-co16-5-32],[@b28-co16-5-32]. Three additional trials [@b17-co16-5-32],[@b23-co16-5-32],[@b34-co16-5-32] reported that 12%--23% of enrolled patients had transformed [nhl]{.smallcaps}, but they did not provide outcomes data for that subgroup of patients. An integrated pooled analysis of five of these studies [@b5-co16-5-32],[@b12-co16-5-32],[@b19-co16-5-32],[@b28-co16-5-32],[@b34-co16-5-32] reported outcomes unique to this subgroup of patients [@b43-co16-5-32],[@b44-co16-5-32],[@b45-co16-5-32]. In this population of 71 evaluable patients with transformed [nhl]{.smallcaps}, the median time from diagnosis to therapy was 74 months, and the median time from transformation was 21 months [@b45-co16-5-32].

3.1.3 Response Rate
-------------------

In previously treated patients, objective response rates ranged from 85% to 100%, with complete response ([cr]{.smallcaps}) rates of 20%--84% [@b5-co16-5-32],[@b8-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b17-co16-5-32],[@b19-co16-5-32],[@b22-co16-5-32],[@b23-co16-5-32],[@b28-co16-5-32],[@b32-co16-5-32],[@b34-co16-5-32],[@b39-co16-5-32],[@b40-co16-5-32] ([Table IV](#tIV-co16-5-32){ref-type="table"}). In the randomized trial [@b22-co16-5-32], a statistically significant difference was observed in objective response between the ^131^I--tositumomab group and the unlabelled tositumomab group (55% vs. 19%), with [cr]{.smallcaps} rates of 33% versus 8% (statistical significance not reported). Response rates in rituximab-naïve patients ranged from 57% [@b19-co16-5-32] to 100% [@b8-co16-5-32] with [cr]{.smallcaps} rates from 20% [@b5-co16-5-32] to 83% [@b8-co16-5-32]. Response to ^131^I--tositumomab appeared to compare favourably with the response to the preceding line of therapy (chemotherapy alone) [@b5-co16-5-32]. For patients that had relapsed after or were refractory to rituximab (with or without chemotherapy), response rates were 65% [@b34-co16-5-32] and 72% [@b39-co16-5-32] respectively.

The response rates were 65% [@b40-co16-5-32] and 87% [@b17-co16-5-32] in the trials that treated patients with ^131^I--tositumomab as part of multi-agent chemotherapy conditioning for [asct]{.smallcaps}, with [cr]{.smallcaps} rates of 57% [@b40-co16-5-32] and 77% [@b17-co16-5-32].

One trial treated patients with more than 25% bone marrow involvement (a relative contraindication to the use of ^131^I--tositumomab) and observed an objective response rate of 18% in 11 patients [@b32-co16-5-32].

A pooled analysis of five trials [@b43-co16-5-32],[@b44-co16-5-32],[@b45-co16-5-32] provided response data for the subgroup of patients with transformed [nhl]{.smallcaps}. A pooled response rate of 39% with a [cr]{.smallcaps} rate of 25% was reported.

3.1.4 Time to Progression
-------------------------

In previously treated patients, [ttp]{.smallcaps} data were reported for ten trials ([Table IV](#tIV-co16-5-32){ref-type="table"}). One randomized trial [@b22-co16-5-32] reported that median [ttp]{.smallcaps} was longer in the ^131^I--tositumomab arm as compared with the unlabelled tositumomab arm (6.3 months vs. 5.5 months, *p* = 0.031). Six single- arm trials of patients who were previously treated with chemotherapy or rituximab, or both [@b5-co16-5-32],[@b12-co16-5-32],[@b19-co16-5-32],[@b28-co16-5-32],[@b34-co16-5-32], or with prior ^131^I--tositumomab [@b23-co16-5-32], reported median [ttp]{.smallcaps} ranges from 8.4 months to 12 months. One trial reported a 1-year progression-free survival of 66% [@b11-co16-5-32].

3.1.5 Response Duration
-----------------------

Data on response duration in previously treated patients were reported in eight trials ([Table IV](#tIV-co16-5-32){ref-type="table"}). In the randomized trial [@b22-co16-5-32], median response duration was not reached in the ^131^I--tositumomab arm; it was 28.1 months in the unlabelled tositumomab arm (*p* = not reported). In previously treated patients who had not received rituximab, median response duration ranged from 6.5 months [@b5-co16-5-32] to 15 months [@b6-co16-5-32]. In the trial that compared ^131^I--tositumomab response with that attained for last chemotherapy regimen in the same patients [@b5-co16-5-32], 17 of 60 patients achieved a response duration after ^131^I--tositumomab that was equivalent to their most recent lymphoma treatment; 53% achieved a longer response duration after ^131^I--tositumomab (*p* \< 0.001). In individuals with transformed [nhl]{.smallcaps}, the pooled analysis of five trials documented a median response duration of 20 months. In addition, of the 25% of individuals who attained a [cr]{.smallcaps}, median response duration reached 36.5 months [@b45-co16-5-32].

3.1.6 Survival
--------------

In the trials that included patients who had [nhl]{.smallcaps} relapsed or refractory to chemotherapy without rituximab, the median [os]{.smallcaps} ranged from 21 months [@b8-co16-5-32] to 41 months [@b12-co16-5-32], with two trials reporting that the median [os]{.smallcaps} was not reached at 12 months [@b11-co16-5-32] and 36 months [@b28-co16-5-32] of follow-up ([Table IV](#tIV-co16-5-32){ref-type="table"}). In patients with disease that was relapsed or refractory to rituximab, median [os]{.smallcaps} had not yet been reached at 39 months [@b34-co16-5-32]. In patients who received ^131^I--tositumomab conditioning for [asct]{.smallcaps}, one trial reported a median [os]{.smallcaps} of 36 months [@b40-co16-5-32], and another trial reported a 2-year [os]{.smallcaps} of 83% [@b17-co16-5-32].

3.1.7 Quality of Life
---------------------

Only one of the thirteen trials of ^131^I--tositumomab in previously treated patients reported data on [qol]{.smallcaps} [@b20-co16-5-32]. The European Organization for Research and Treatment of Cancer quality of life questionnaire was administered to the patient cohort receiving ^131^I--tositumomab after previous lymphoma treatment without rituximab. The authors reported that the scales for emotional function, social function, global health status, nausea/vomiting, and appetite loss demonstrated statistically significant improvements at one or more time points; however, no data or *p* values were reported.

3.1.8 Adverse Events
--------------------

The randomized trial [@b22-co16-5-32] comparing ^131^I--tositumomab with unlabelled tositumomab reported comparative grade 4 hematologic toxicities. Thrombocytopenia (12% vs. 0%), neutropenia (17% vs. 3%), and anemia (5% vs. 0%) occurred more frequently with radioimmunotherapy, although whether these differences were statistically significant was not reported ([Table V](#tV-co16-5-32){ref-type="table"}).

The rates of adverse events were similar in patients who had [@b34-co16-5-32],[@b39-co16-5-32] and who had not [@b5-co16-5-32],[@b8-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b19-co16-5-32],[@b28-co16-5-32] received prior rituximab. Myelosuppression was common, but tended to be delayed in onset, with cytopenia nadirs occurring 7--9 weeks after treatment. Eight trials reported on the rate of infection, with grades 1--4 infections occurring in 21%--55% of patients [@b5-co16-5-32],[@b8-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b19-co16-5-32],[@b23-co16-5-32],[@b34-co16-5-32]. The rate of hospitalization from infection was reported in three trials and ranged from 2% to 15% [@b5-co16-5-32],[@b23-co16-5-32],[@b28-co16-5-32]. Non-hematologic toxicity was common (reported in 80% of patients), generally mild, and related to drug infusion. Grades 1 and 2 adverse events occurred in a high proportion of patients in all trials, with the most common events being headache, fever, chills, infection, nausea, and vomiting. [Table V](#tV-co16-5-32){ref-type="table"} summarizes these adverse events.

The rate of [hama]{.smallcaps} response was reported in ten single-arm trials, occurring in 0%--35% of patients [@b5-co16-5-32],[@b8-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b19-co16-5-32],[@b17-co16-5-32],[@b23-co16-5-32],[@b28-co16-5-32],[@b34-co16-5-32],[@b40-co16-5-32]. Hypothyroidism was reported in six trials, and for the ^131^I--tositumomab arm of the randomized trial, it occurred in 7%--42% of patients [@b5-co16-5-32],[@b8-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b22-co16-5-32],[@b23-co16-5-32],[@b34-co16-5-32].

The rate of myelodysplastic syndrome ([mds]{.smallcaps}) was reported in eight trials and ranged from 0% to 9% [@b5-co16-5-32],[@b8-co16-5-32],[@b9-co16-5-32],[@b11-co16-5-32],[@b12-co16-5-32],[@b23-co16-5-32],[@b28-co16-5-32],[@b34-co16-5-32],[@b40-co16-5-32]. One study that included patients from six trials and an expanded access program reported on [mds]{.smallcaps} and acute myeloid leukemia ([aml]{.smallcaps}) in patients treated with ^131^I--tositumomab [@b16-co16-5-32]: 35 of 1071 patients developed [mds]{.smallcaps} or [aml]{.smallcaps} for an annualized incidence of 1.4% per year (95% confidence interval: 1.0% to 2.0% per year).

3.1.9 Prognostic Factors
------------------------

Predictors for overall response included tumour burden below 500 g [@b5-co16-5-32], grade [i]{.smallcaps} or [ii]{.smallcaps} disease and tumour size 7 cm or less [@b34-co16-5-32], lymph node diameter less than 5 cm [@b28-co16-5-32], low-grade [nhl]{.smallcaps} [@b5-co16-5-32],[@b12-co16-5-32], bone marrow involvement [@b5-co16-5-32], fewer than 4 prior chemotherapy regimens [@b5-co16-5-32], and no prior radiotherapy [@b5-co16-5-32]. The prior use of 2 or more chemotherapy regimens was associated with a shorter duration of remission [@b28-co16-5-32].

3.1.10 Dosimetry and Imaging
----------------------------

Dosimetry is a method of estimating the dose of radiation administered to specific organs. Imaging refers to the evaluation of gamma images to ensure that drug biodistribution is appropriate [@b46-co16-5-32]. Dosimetry is required to determine the dose of ^131^I--tositumomab to be administered [@b21-co16-5-32],[@b47-co16-5-32], and it was used in all trials in patients with previously treated [nhl]{.smallcaps}. No dose--response relationship was noted between absorbed dose and tumour response [@b21-co16-5-32]. Also, no correlation was observed between total body tumour burden and objective response or toxicity [@b21-co16-5-32].

3.2 Patients with Previously Untreated NHL
------------------------------------------

### 3.2.1 Study Quality

No randomized controlled trials of ^131^I--tositumomab in patients with previously untreated [nhl]{.smallcaps} were identified. All of the five studies located were single-arm noncomparative phase [ii]{.smallcaps} trials with sample sizes ranging from 13 patients to 90 patients [@b25-co16-5-32],[@b27-co16-5-32],[@b29-co16-5-32],[@b31-co16-5-32],[@b35-co16-5-32]. Median follow-up ranged from 11 months to 61.2 months.

### 3.2.2 Study Characteristics

[Table VI](#tVI-co16-5-32){ref-type="table"} details the study and patient characteristics of trials of ^131^I--tositumomab in patients with previously untreated [nhl]{.smallcaps}.

### 3.2.3 Response Rate

[Table VII](#tVII-co16-5-32){ref-type="table"} presents response data for the five trials of ^131^I--tositumomab in the previously untreated patient population. In the four trials of ^131^I--tositumomab alone [@b35-co16-5-32] or after chemotherapy [@b25-co16-5-32],[@b29-co16-5-32],[@b31-co16-5-32], objective response rates ranged from 90% to 100%, with [cr]{.smallcaps} rates from 67% to 83%. In a trial of sequential therapy with ^131^I--tositumomab followed by [chop]{.smallcaps} (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy (×6 cycles) in patients with mantle-cell [nhl]{.smallcaps}, the response rate was 83% after ^131^I--tositumomab ([cr]{.smallcaps} rate: 50%) and by intention-to-treat analysis, the response rate was 75% after [chop]{.smallcaps} (all of which were [crs]{.smallcaps}) [@b27-co16-5-32].

### 3.2.4 Time to Progression

[Table VII](#tVII-co16-5-32){ref-type="table"} presents data on [ttp]{.smallcaps}. One trial reported a median [ttp]{.smallcaps} of 73.2 months [@b35-co16-5-32] and another reported a 2-year progression-free survival of 81% [@b25-co16-5-32]. Median [ttp]{.smallcaps} had not yet been reached in two other trials in which the median follow-up periods were 28 and 53 months [@b29-co16-5-32],[@b31-co16-5-32].

### 3.2.5 Response Duration

Only one trial [@b27-co16-5-32] reported median response duration, which had not yet been reached after a median follow-up of 11 months ([Table VII](#tVII-co16-5-32){ref-type="table"}). Among the subset of patients who experienced a [cr]{.smallcaps} [@b35-co16-5-32], 40 of 57 had experienced an ongoing [cr]{.smallcaps} for 4.3--7.7 years. A third trial [@b29-co16-5-32] reported that the median duration of [cr]{.smallcaps} was not reached after a median follow-up of 52.8 months, with 72% of 29 patients with a [cr]{.smallcaps} remaining in remission.

### 3.2.6 Survival

Two trials reported survival data for previously untreated patients ([Table VII](#tVII-co16-5-32){ref-type="table"}). One reported a 5-year [os]{.smallcaps} of 89% [@b35-co16-5-32], and another reported a 2-year [os]{.smallcaps} of 97% [@b25-co16-5-32].

### 3.2.7 Quality of Life

None of the trials of patients with previously untreated [nhl]{.smallcaps} reported data on [qol]{.smallcaps}.

### 3.2.8 Adverse Events

[Table VIII](#tVIII-co16-5-32){ref-type="table"} summarizes adverse events in the previously untreated population. Grades 3 and 4 thrombocytopenia ranged from 11% to 29%; neutropenia, from 13% to 34%; and anemia, from 0% to 3% [@b25-co16-5-32],[@b29-co16-5-32],[@b31-co16-5-32],[@b35-co16-5-32]. Grade 3 infection occurred in 2% of patients [@b25-co16-5-32], and febrile neutropenia was reported as 0% in one trial [@b35-co16-5-32] and 42% in another [@b27-co16-5-32]. One trial reported a 0% rate of hospitalization as a result of infection [@b35-co16-5-32]; no other trials reported hospitalization data.

Elevated thyroid-stimulating hormone occurred in 7%--12% of patients [@b25-co16-5-32],[@b29-co16-5-32],[@b35-co16-5-32], and [hama]{.smallcaps} occurred in 0%--63% [@b27-co16-5-32],[@b29-co16-5-32],[@b31-co16-5-32],[@b35-co16-5-32], with [mds]{.smallcaps} or [aml]{.smallcaps} occurring in 0%--3% of patients [@b25-co16-5-32],[@b31-co16-5-32],[@b35-co16-5-32].

### 3.2.9 Prognostic Factors

One trial reported on predictive factors [@b35-co16-5-32]. Nodal diameters of 5 cm or more were associated with lower response rates, and bone marrow involvement was also associated with lower response rates. Only bone marrow involvement had a significant effect on progression-free survival, predicting for a worse outcome.

### 3.2.10 Dosimetry and Imaging

All of the trials that enrolled patients with previously untreated [nhl]{.smallcaps} used dosimetry and imaging in the trial protocol. Dosimetry is part of the ^131^I--tositumomab regimen. One publication [@b38-co16-5-32] provided updated data on patients in three other publications [@b36-co16-5-32],[@b37-co16-5-32],[@b47-co16-5-32] and on an additional 19 patients. The authors reported that, for patients with previously untreated follicular [nhl]{.smallcaps} who received ^131^I--tositumomab, those with tumours receiving the highest radiation doses were more likely to achieve a [cr]{.smallcaps}; however, that association was not statistically significant.

4. DISCUSSION
=============

The development of the monoclonal antibody rituximab has significantly advanced the treatment of lymphomas that express the target CD20 antigen. The anti-lymphoma benefit of rituximab is likely multifactorial, including antibody- and complement-dependent cellular cytotoxicity mechanisms [@b4-co16-5-32]. In addition to these immunobiologic effects, radioimmunoconjugates have the potential to direct radiation exclusively to the site of disease involvement, minimizing exposure to uninvolved organs. The adoption of these agents will depend on whether the incremental anti-lymphoma activity can translate into improved long-term outcomes without undue toxicity.

Patients with indolent lymphoma are treated episodically with chemotherapy, immunotherapy, or radiation often over a period of many years, sometimes decades. Therapy is initially highly effective in palliating symptoms and relieving potentially life-threatening complications, but it is not curative. Over time, response rates diminish and become less durable. The outcome for patients who are refractory to rituximab is particularly poor, and few alternative treatment options remain. In this context of heavily pretreated disease, the evidence supports the use of ^131^I--tositumomab. ^131^I--Tositumomab demonstrated significant anti-lymphoma activity in six single-arm trials in patients with [nhl]{.smallcaps} relapsed or refractory to chemotherapy without rituximab and in two single-arm phase [ii]{.smallcaps} trials in patients with [nhl]{.smallcaps} relapsed or refractory to rituximab with or without chemotherapy.

For most of this heavily pretreated patient population, therapeutic options have been exhausted. A standard comparison therefore does not exist. However, one trial used each patient as a paired self control for comparing duration of response with the patient's last qualifying chemotherapy regimen [@b5-co16-5-32]. That trial reported a significant difference in objective response (65% with ^131^I--tositumomab vs. 28% with last chemotherapy), and 53% of patients had a longer response duration after ^131^I--tositumomab than after their most recent chemotherapy. This longer response may represent a beneficial effect on the natural history of the disease because, typically, a lower response rate and shorter duration of response are observed with each successive treatment. In addition, a proportion of responders had very long durable remissions. For patients with a [cr]{.smallcaps}, median duration of response was 47.2 months as compared with only 4.8 months for their last qualifying chemotherapy. Given the limited available treatment options for pretreated patients, the use of ^131^I--tositumomab may offer benefit when other treatments (including rituximab) have failed.

The role of ^131^I--tositumomab in individuals with transformed low-grade [nhl]{.smallcaps} is also of interest, given the poor prognosis associated with currently available therapies. An integrated analysis of patients with transformation across five trials documented moderate response rates and a median response duration of 20 months, results that were commensurate with the heavily pretreated low-grade population [@b43-co16-5-32]. However, this small and selected population of patients with an extended time from transformation until treatment with ^131^I--tositumomab may not be reflective of all patients with transformed [nhl]{.smallcaps} [@b45-co16-5-32], and further prospective data for this unique presentation are warranted.

The data do not currently identify whether there is a differential benefit between the various indolent histologies (follicular vs. non-follicular) enrolled in these pivotal trials. The data supporting the use of ^131^I--tositumomab in previously untreated patients with [nhl]{.smallcaps} are limited. No randomized controlled trials have compared ^131^I--tositumomab with standard therapy, and therefore the use of ^131^I--tositumomab in this patient population should be reserved until evidence becomes available supporting improved clinical outcomes with ^131^I--tositumomab as compared with current standard therapies.

The evidence for ^131^I--tositumomab as part of a conditioning regimen before [asct]{.smallcaps} is limited to two single-arm trials [@b17-co16-5-32],[@b40-co16-5-32]. Although encouraging, the limited data preclude any clear conclusions of benefit in that setting.

The toxicities of ^131^I--tositumomab are predictable. The main toxicity is hematologic, with delayed-onset cytopenias whose nadirs occur at 7--9 weeks from treatment. Particular attention to severe myelosuppression is warranted for patients with known bone marrow involvement and thrombocytopenia preceding therapy. Dose reductions are required if platelets reach 100--150×10^9^/L, and the drug should not be administered if platelets are less than 100×10^9^/L, absolute neutrophil count is less than 1.5×10^9^/L, or bone marrow involvement is greater than 25%. The annualized incidence of [mds]{.smallcaps} and [aml]{.smallcaps} in patients with previously treated [nhl]{.smallcaps} is 1.4% per year and would be considered acceptable in this group of patients who have often received prior leukemogenic anti-lymphoma therapies such as alkylating agents. The incidence of [hama]{.smallcaps} varied from 0% to 35% and is of questionable clinical significance.

The evidence has highlighted a number of predictors for response to radioimmunotherapy. Common predictors for response include indolent-histology disease (compared with transformed histology), non-bulky disease, and fewer prior therapies. However, these results should be considered hypothesis-generating at this time, given the limited sample sizes on which the subgroup analyses were based.

The final question that guided this review was the role of dosimetry in establishing the safety and efficacy of ^131^I--tositumomab. Although dosimetric findings did not correlate with tumour response, dosimetry was performed in all clinical studies involving this agent and is currently mandated in North American and European jurisdictions to determine the patient-specific therapeutic dose. Although there may be logistic barriers to the performance of dosimetry, especially in smaller centres of practice, these limitations are out of the scope of the present review.

Currently, no comparative data addressing the use of one radioimmunoconjugate over another are available. Another radiolabelled anti-CD20 antibody, ^90^Y-ibritumomab tiuxetan (Zevalin: [idec]{.smallcaps} Pharmaceuticals, San Diego, CA, U.S.A.), is being studied predominantly in indolent and transformed lymphoma. Important differences in radiation characteristics and dosimetry requirements may limit the class generalizability of these antibodies.

The strengths of the present review include the use of validated methods for the performance of systematic reviews, extension of the literature search to include preliminary abstract data to minimize publication bias, and objective data abstraction according to predefined outcome questions. However, the review does have limitations. For most of the trials, we did not formally appraise study quality because they were phase [ii]{.smallcaps} studies and several were reported only in abstract form. This lack of appraisal limited the discrimination and utility of any methodologic grading scores. Also, the variability of the data precluded any pooling of results or use of meta-analytic summary techniques. We appreciate that the data come largely from single-arm studies and that the results are subject to selection bias; however, we have tempered our conclusions regarding this agent to reflect the currently available evidence. Finally, we acknowledge that the evidence regarding the role of ^131^I--tositumomab will continue to mature and evolve beyond this original systematic review and summary document. A current listing of phase [iii]{.smallcaps} trials is provided in [Table IX](#tIX-co16-5-32){ref-type="table"}, and we invite practitioners and patients to review the Web site of the [pebc]{.smallcaps} ([www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10269](www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10269)) to remain abreast of the update process mandated for these guidelines.

Despite limitations, the data suggest a role for ^131^I--tositumomab in selected patients with [nhl]{.smallcaps}. The current evidence supports a role in the management of indolent lymphoma refractory to prior therapy that includes rituximab with or without chemotherapy. The precise role of ^131^I--tositumomab within the lymphoma armamentarium will undoubtedly continue to evolve.

Funding for this review process was provided by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care, Government of Ontario, Canada. The Hematology [dsg]{.smallcaps} thanks Dr. Stacey Hubay for reviewing the document and providing important input.

Also see [Appendix A](#app1-co16-5-32){ref-type="app"}, which describes an update to the original search and the articles located as a result.

The Program in Evidence-Based Care is supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. The Program in Evidence-Based Care is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

To ensure that our systematic review and conclusions remained valid, we updated the [medline]{.smallcaps} literature search outlined in [Table I](#tI-co16-5-32){ref-type="table"} to May 10, 2009, from 2005, with a focus on randomized controlled trials and single-arm noncomparative studies. The same inclusion criteria that defined the original search were again applied. The new literature search identified 165 citations. Seven full publications met the inclusion criteria. No randomized phase [iii]{.smallcaps} studies were identified for this time period. All of the reports were single-arm phase [ii]{.smallcaps} reports. One publication, an integrated analysis of five pivotal studies on ^131^I--tositumomab, had already been included in the systematic review [@b44-co16-5-32]. Another study provided a longer-term update of a published report identified in the review [@b26-co16-5-32]; three other reports represented the final publication of abstracts identified in the review [@b33-co16-5-32],[@b24-co16-5-32],[@b30-co16-5-32]. Thus, only two new single-arm studies were discovered [@b41-co16-5-32],[@b42-co16-5-32] (see [Table A-I](#tAI-co16-5-32){ref-type="table"}). The data from the updated reports and the two novel studies do not affect the summary answers to the questions that guided the original systematic review.

###### 

Novel and updated trials of ^131^I--tositumomab (^131^[itb]{.smallcaps}) in patients with non-Hodgkin lymphoma

  Reference                                                                                Study type   Intervention                                                                                                                                Pts   [or]{.smallcaps}                               [cr]{.smallcaps}                                                  Median results (months) for                      
  ---------------------------------------------------------------------------------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------- ----- ---------------------------------------------- ---------------------------------------------- ------------------ ----------------------------- ------------------ ------------------
  *Previously untreated patients*                                                                                                                                                                                                                                                                                                                                                                                           
   Leonard *et al.,* 2005[@b30-co16-5-32] (final report after abstract [@b29-co16-5-32])   Single-arm   Fludarabine followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                                    35    100                                            86                                             Not yet reached    [nr]{.smallcaps}              [nr]{.smallcaps}   58
   Press *et al.,* 2006[@b26-co16-5-32]                                                    Single-arm   [chop]{.smallcaps} followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                             90    91                                             69                                             5-Year: 67%        [nr]{.smallcaps}              5-Year: 87%        5.1 Years
  *^131^[itb]{.smallcaps}in alternative regimens (previously treated patients)*                                                                                                                                                                                                                                                                                                                                             
   Kaminski *et al.,* 2005[@b24-co16-5-32] (final report after abstract[@b23-co16-5-32])   Single-arm   ^131^[itb]{.smallcaps} phase [i]{.smallcaps} (total body dose: [nr]{.smallcaps}), previous treatment with ^131^[itb]{.smallcaps}            32    56                                             25                                             11.8               15.2                          [nr]{.smallcaps}   35
   Mones *et al.,* 2007[@b33-co16-5-32] (final report after abstract [@b32-co16-5-32])     Single-arm   ^131^[itb]{.smallcaps} phase [i]{.smallcaps} \[total body dose: 45 cGy (dose escalation)\], bone marrow involvement \> 25%                  11    18                                             [nr]{.smallcaps}                               [nr]{.smallcaps}   [nr]{.smallcaps}              [nr]{.smallcaps}   [nr]{.smallcaps}
  *Relapsed or refractory to chemotherapy (previously treated patients)*                                                                                                                                                                                                                                                                                                                                                    
   Buchegger *et al.,* 2006[@b41-co16-5-32]                                                Single-arm   ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets ≤149,000/mm^3^)                                                        18    81[b](#tfn37-co16-5-32){ref-type="table-fn"}   50[b](#tfn37-co16-5-32){ref-type="table-fn"}   22.5               [nr]{.smallcaps}              Not yet reached    48
  *^131^[itb]{.smallcaps}conditioning for autologous stem cell transplantation*                                                                                                                                                                                                                                                                                                                                             
   Gopal *et al.,* 2006[@b42-co16-5-32]                                                    Single-arm   ^131^[itb]{.smallcaps} (total body dose: 25--27 cGy[c](#tfn38-co16-5-32){ref-type="table-fn"}), plus autologous stem cell transplantation   24    67                                             54                                             3-Year: 59%        [nr]{.smallcaps}              3-Year: 51%        2.9 Years

Number included in the analysis.

Calculated based on 31 patients that were evaluable for response.

Dose to the critical normal organ predicted to receive the highest radiation exposure based on biodistribution study.

Pts = patients; [or]{.smallcaps}= complete response, unconfirmed complete response, and partial response; [cr]{.smallcaps}= complete response and unconfirmed complete response; [ttp]{.smallcaps}= time to progression; [os]{.smallcaps}= overall response; [nr]{.smallcaps}= not reported; [chop]{.smallcaps}= cyclophosphamide, doxorubicin, vincristine, prednisone.

###### 

Literature search strategy

  Step   Search term
  ------ --------------------------------------------------------------------
  1      zevalin.mp.
  2      ibritumomab tiuxetan.mp.
  3      anti-CD20.mp.[a](#tfn1-co16-5-32){ref-type="table-fn"}
  4      antiCD20.mp.[a](#tfn1-co16-5-32){ref-type="table-fn"}
  5      antiCD-20.mp.[a](#tfn1-co16-5-32){ref-type="table-fn"}
  6      idec-y2b8.mp.
  7      idecy2b8.mp.
  8      idec-2b8.mp.
  9      idec2b8.mp.
  10     idec-In2b8.mp.
  11     idecIn2b8.mp.
  12     idec-129.mp.
  13     idec129.mp.
  14     or/1--13
  15     lymphoma.mp.
  16     exp lymphoma/
  17     exp lymphoma, large-cell/[b](#tfn2-co16-5-32){ref-type="table-fn"}
  18     or/15--17
  19     14 and 18
  20     limit 19 to human
  21     limit 20 to English language
  22     comment.pt.
  23     letter.pt.
  24     editorial.pt.
  25     or/22--24
  26     21 not 25[c](#tfn3-co16-5-32){ref-type="table-fn"}
  27     20 not 21
  28     27 not 25^d^

Included in the original literature search (July 2003).

Included in the May 2004 literature search.

Results for citations in the English language.

###### 

Primary and additional publications of trials included in this systematic review

  Primary publication                                  Publications with additional information
  ---------------------------------------------------- -----------------------------------------------------------------------------------
  Press *et al.,* 1993[@b8-co16-5-32]                  Liu *et al.,* 1998[@b9-co16-5-32]
                                                       Gopal *et al.,* 2003[@b10-co16-5-32]
  Press *et al.,* 1995[@b11-co16-5-32]                 Liu *et al.,* 1998[@b9-co16-5-32]
                                                       Gopal *et al.,* 2003[@b10-co16-5-32]
  Kaminski *et al.,* 2000[@b12-co16-5-32]              Kaminski *et al.,* 1993[@b13-co16-5-32]
                                                       Kaminski *et al.,* 1996[@b14-co16-5-32]
                                                       Wahl *et al.,* 1998[@b15-co16-5-32]
                                                       Bennet *et al.,* 2005[@b16-co16-5-32]
  Press *et al.,* 2000[@b17-co16-5-32]                 Gopal *et al.,* 2002[@b18-co16-5-32]
  Vose *et al.,* 2000[@b19-co16-5-32]                  Kaminski *et al.,* 2001[@b20-co16-5-32] (abstract)
                                                       Sgouros *et al.,* 2003[@b21-co16-5-32]
                                                       Bennet *et al.,* 2005[@b16-co16-5-32]
  Kaminski *et al.,* 2001[@b5-co16-5-32]               Kaminski *et al.,* 2001[@b20-co16-5-32] (abstract)
                                                       Sgouros *et al.,* 2003[@b21-co16-5-32]
                                                       Bennet *et al.,* 2005[@b16-co16-5-32]
  Davis *et al.,* 2003[@b22-co16-5-32] (abstract)      Bennet *et al.,* 2005[@b16-co16-5-32]
  Kaminski *et al.,* 2003[@b23-co16-5-32] (abstract)   Kaminski *et al.,* 2005[@b24-co16-5-32],[a](#tfn4-co16-5-32){ref-type="table-fn"}
  Press *et al.,* 2003[@b25-co16-5-32]                 Press *et al.,* 2006[@b26-co16-5-32],[a](#tfn4-co16-5-32){ref-type="table-fn"}
  Zelenetz *et al.,* 2003[@b27-co16-5-32] (abstract)   None
  Davies *et al.,* 2004[@b28-co16-5-32]                None
  Leonard *et al.,* 2004[@b29-co16-5-32] (abstract)    Leonard *et al.,* 2005[@b30-co16-5-32],[a](#tfn4-co16-5-32){ref-type="table-fn"}
  Link *et al.,* 2004[@b31-co16-5-32] (abstract)       None
  Mones *et al.,* 2004[@b32-co16-5-32] (abstract)      Mones *et al.,* 2007[@b33-co16-5-32],[a](#tfn4-co16-5-32){ref-type="table-fn"}
  Horning *et al.,* 2005[@b34-co16-5-32]               Bennet *et al.,* 2005[@b16-co16-5-32]
  Kaminski *et al.,* 2005[@b35-co16-5-32]              Koral *et al.,* 2000[@b21-co16-5-32]
                                                       Koral *et al.,* 2000[@b36-co16-5-32]
                                                       Koral *et al.,* 2002[@b37-co16-5-32]
                                                       Koral *et al.,* 2003[@b38-co16-5-32]
                                                       Bennet *et al.,* 2005[@b16-co16-5-32]
  Nair *et al.,* 2005[@b39-co16-5-32] (abstract)       None
  Vose *et al.,* 2005[@b40-co16-5-32]                  None

See [Appendix A](#app1-co16-5-32){ref-type="app"} for details regarding this publication.

###### 

Trials of ^131^I tositumomab (^131^[itb]{.smallcaps}) in patients with previously treated non-Hodgkin lymphoma ([nhl]{.smallcaps}): study characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                       Study type     Patient characteristics                                                                                                                                               Intervention                                                                                                                                                                                                                                                                                                                          Pts (*n*)[a](#tfn5-co16-5-32){ref-type="table-fn"}
  ------------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  *Relapsed or refractory to chemotherapy without rituximab*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

   Press *et al.,* 1993[@b8-co16-5-32]                                            Single-arm     CD20+ or CD37+ B-cell [nhl]{.smallcaps} unresponsive to conventional systemic therapy                                                                                 ^131^[itb]{.smallcaps} phase [i]{.smallcaps} \[total body dose: 10--31 Gy (dose escalation)\], autologous stem cell transplantation if needed                                                                                                                                                                                         12[b](#tfn6-co16-5-32){ref-type="table-fn"}

   Press *et al.,* 1995[@b11-co16-5-32]                                           Single-arm     CD20+ [nhl]{.smallcaps} relapsed after at least one chemotherapy regimen                                                                                              ^131^[itb]{.smallcaps} (total body dose: 25--31 cGy), autologous stem cell transplantation or peripheral stem cell transplantation if needed                                                                                                                                                                                          25

   Kaminski *et al.,* 2000[@b12-co16-5-32]                                        Single-arm     Relapsed or refractory CD20+ B-cell [nhl]{.smallcaps}                                                                                                                 ^131^[itb]{.smallcaps} phase [i]{.smallcaps}/[ii]{.smallcaps} (phase [ii]{.smallcaps} total body dose: 75 cGy)                                                                                                                                                                                                                        59

   Vose *et al.,* 2000[@b19-co16-5-32]                                            Single-arm     Low-grade or transformed low-grade CD20+ [nhl]{.smallcaps} relapsed or refractory to at least one anthracycline- or anthracenedione-containing chemotherapy regimen   ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets ≤ 149,000/mm^3^)                                                                                                                                                                                                                                                 47

   Kaminski, 2001[@b5-co16-5-32]                                                  Single-arm     Low-grade or transformed low-grade CD20+ B-cell [nhl]{.smallcaps} relapsed or refractory after at least two prior chemotherapy regimens                               ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                                                                                                                                                                60

   Davis *et al.,* 2003[@b22-co16-5-32] (abstract)                                *Randomized*   Relapsed or refractory CD20+ [nhl]{.smallcaps}                                                                                                                        ^131^[itb]{.smallcaps} (total body dose: [nr]{.smallcaps}) Unlabelled tositumomab                                                                                                                                                                                                                                                     42\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             36

   Davies *et al.,* 2004[@b28-co16-5-32]                                          Single-arm     B-Cell [nhl]{.smallcaps} in first or second recurrence                                                                                                                ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets ≤ 149,000/mm^3^)                                                                                                                                                                                                                                                 44

  *Relapsed or refractory to rituximab with or without chemotherapy*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

   Horning *et al.,* 2005[@b34-co16-5-32]                                         Single-arm     Indolent or transformed [nhl]{.smallcaps} relapsed or refractory to rituximab                                                                                         ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                                                                                                                                                                43

   Nair *et al.,* 2005[@b39-co16-5-32] (abstract)                                 Single-arm     CD20+ [nhl]{.smallcaps} refractory to chemotherapy plus rituximab                                                                                                     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                                                                                                                                                                11

  *^131^[itb]{.smallcaps}conditioning for autologous stem cell transplantation*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Press *et al.,* 2000[@b17-co16-5-32]                                           Single-arm     CD20+ [nhl]{.smallcaps} relapsed or refractory to previous chemotherapy, bone marrow involvement \< 25%                                                               ^131^[itb]{.smallcaps} \[total body dose: 20--27 Gy (dose escalation)\], followed by etoposide (60 mg/kg), plus cyclophosphamide (100 mg/kg), plus autologous stem cell transplantation                                                                                                                                               52

   Vose *et al.,* 2005[@b40-co16-5-32]                                            Single-arm     Previously treated chemotherapy-resistant CD20+ aggressive [nhl]{.smallcaps}                                                                                          ^131^[itb]{.smallcaps} \[total body dose: 30--75 cGy (dose escalation)\], followed by [beam]{.smallcaps} (carmustine 300 mg/m^2^ day 1; plus etoposide 100 mg/m^2^ twice daily, days 2--5; plus cytarabine 100 mg/m^2^ twice daily, days 2--5; plus melphalan 140 mg/m^2^ day 6), plus autologous stem cell transplantation (day 7)   23

  *^131^[itb]{.smallcaps}in alternative regimens*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

   Kaminski *et al.,* 2003[@b23-co16-5-32] (abstract)                             Single-arm     Low-grade or transformed low-grade [nhl]{.smallcaps} previously treated with ^131^[itb]{.smallcaps}                                                                   ^131^[itb]{.smallcaps} phase [i]{.smallcaps} (total body dose: [nr]{.smallcaps})                                                                                                                                                                                                                                                      32

   Mones *et al.,* 2004[@b32-co16-5-32] (abstract)                                Single-arm     Relapsed or refractory low-grade [nhl]{.smallcaps}, bone marrow involvement \> 25%                                                                                    ^131^[itb]{.smallcaps} phase [i]{.smallcaps} \[total body dose: 45cGy (10 cGy dose-escalation increments)\]                                                                                                                                                                                                                           11
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Randomized or enrolled/eligible.

Of the 43 enrolled patients, 19 received therapeutic doses, and only 12 of the 19 received ^131^[itb]{.smallcaps}.

Pts = patients; [nr]{.smallcaps}= not reported.

###### 

Trials of ^131^I--tositumomab (^131^[itb]{.smallcaps}) in patients with previously treated non-Hodgkin lymphoma: response and survival

  Reference                                                                       Study type     Intervention                                                                                                                                                                                         Pts (n)                                        [or]{.smallcaps} (%)                           [cr]{.smallcaps} (%)                                                                          Median results (months) for                                                  
  ------------------------------------------------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------------------- ---------------------------------------------- ------------------
  *Relapsed or refractory to chemotherapy without rituximab*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Press *et al.,* 1993[@b8-co16-5-32]                                            Single-arm     ^131^[itb]{.smallcaps} phase [i]{.smallcaps} \[total body dose: 10--31 Gy (dose escalation)\]                                                                                                        12[a](#tfn8-co16-5-32){ref-type="table-fn"}    100[b](#tfn9-co16-5-32){ref-type="table-fn"}   83                                             [nr]{.smallcaps}                               11                            21+                                            26
   Press *et al.,* 1995[@b11-co16-5-32]                                           Single-arm     ^131^[itb]{.smallcaps} (total body dose: 27 Gy)                                                                                                                                                      21[c](#tfn10-co16-5-32){ref-type="table-fn"}   90[b](#tfn9-co16-5-32){ref-type="table-fn"}    76                                             Not yet reached                                [nr]{.smallcaps}              Not yet reached                                12
   Kaminski *et al.,* 2000[@b12-co16-5-32]                                        Single-arm     ^131^[itb]{.smallcaps} phase [i]{.smallcaps}/[ii]{.smallcaps} (phase [ii]{.smallcaps} total body dose: 75 cGy)                                                                                       59                                             71                                             34                                             12                                             [nr]{.smallcaps}              41[d](#tfn11-co16-5-32){ref-type="table-fn"}   37.2
   Vose *et al.,* 2000[@b19-co16-5-32]                                            Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets ≤ 149,000/mm^3^)                                                                                                                47                                             57                                             32                                             11.6                                           9.9                           36                                             [nr]{.smallcaps}
   Kaminski *et al.,* 2001[@b5-co16-5-32]                                         Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65cGy if platelets \< 150,000/mm^3^)                                                                                                                60                                             65                                             20                                             8.4                                            6.5                           22.8                                           [nr]{.smallcaps}
   Davis *et al.,* 2003[@b22-co16-5-32] (abstract)                                *Randomized*   ^131^[itb]{.smallcaps} (total body dose: [nr]{.smallcaps})                                                                                                                                           42                                             55                                             33                                             6.3                                            Not yet reached               [nr]{.smallcaps}                               42.6
                                                                                                 Unlabelled tositumomab                                                                                                                                                                               36                                             19                                             8                                              5.5                                            28.1                          [nr]{.smallcaps}                               
                                                                                                                                                                                                                                                                                                                                                     *p*=0.002                                                                                     *p*=0.031                                                                                                                   
   Davies *et al.,* 2004[@b28-co16-5-32]                                          Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets ≤ 149,000/mm^3^)                                                                                                                41[e](#tfn12-co16-5-32){ref-type="table-fn"}   76                                             49                                             9.6                                            15                            Not yet reached                                36
  *Relapsed or refractory to rituximab with or without chemotherapy*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Horning *et al.,* 2005[@b34-co16-5-32]                                         Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                               40[f](#tfn13-co16-5-32){ref-type="table-fn"}   65                                             38                                             10.4                                           [nr]{.smallcaps}              Not yet reached                                39
   Nair *et al.,* 2005[@b39-co16-5-32] (abstract)                                 Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                               11                                             72                                             27                                             [nr]{.smallcaps}                               [nr]{.smallcaps}              [nr]{.smallcaps}                               26
  ^131^*[itb]{.smallcaps}conditioning for autologous stem cell transplantation*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   Press *et al.,* 2000[@b17-co16-5-32]                                           Single-arm     ^131^[itb]{.smallcaps} \[total body dose: 20--27 cGy (dose escalation)\], followed by etoposide, plus cyclophosphamide, plus autologous stem cell transplantation                                    52                                             87[g](#tfn14-co16-5-32){ref-type="table-fn"}   77[g](#tfn14-co16-5-32){ref-type="table-fn"}   40[h](#tfn15-co16-5-32){ref-type="table-fn"}   [nr]{.smallcaps}              2-Year: 83%                                    [nr]{.smallcaps}
   Vose *et al.,* 2005[@b40-co16-5-32]                                            Single-arm     ^131^[itb]{.smallcaps} \[total body dose: 30--75 cGy (dose escalation)\], followed by [beam]{.smallcaps} (carmustine, etoposide, cytarabine, melphalan), plus autologous stem cell transplantation   23                                             65                                             57                                             34[i](#tfn16-co16-5-32){ref-type="table-fn"}   [nr]{.smallcaps}              34[d](#tfn11-co16-5-32){ref-type="table-fn"}   38
  ^131^*[itb]{.smallcaps}in alternative regimens*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   Kaminski *et al.,* 2003[@b23-co16-5-32] (abstract)                             Single-arm     ^131^[itb]{.smallcaps} phase [i]{.smallcaps} (total body dose: [nr]{.smallcaps}), previous treatment with ^131^[itb]{.smallcaps}                                                                     32                                             56                                             22                                             11.8                                           10.7                          [nr]{.smallcaps}                               26
   Mones *et al.,* 2004[@b32-co16-5-32] (abstract)                                Single-arm     ^131^[itb]{.smallcaps} phase [i]{.smallcaps} \[total body dose: 45 cGy (dose escalation)\], bone marrow involvement \> 25%                                                                           11                                             18                                             [nr]{.smallcaps}                               [nr]{.smallcaps}                               [nr]{.smallcaps}              [nr]{.smallcaps}                               [nr]{.smallcaps}

Only 12 of the 43 enrolled patients received a therapeutic dose of ^131^[itb]{.smallcaps}.

Includes patients with complete, partial, or minor response.

Of 25 enrolled patients, 4 did not receive treatment and were not included in the response and survival data analysis.

Estimated from Kaplan--Meier survival curve.

Of 44 enrolled patients, 3 did not receive treatment and were not included in the final analysis.

Of 43 enrolled patients, 3 did not receive treatment and were not included in the final analysis.

Response rates were calculated based on 31 patients that were evaluable for response.

Estimated from Kaplan--Meier progression-free survival curve.

Event-free survival, estimated from Kaplan--Meier event-free survival curve.

###### 

Trials of ^131^I tositumomab (^131^[itb]{.smallcaps}) in patients with previously treated non-Hodgkin lymphoma: adverse events

  Reference                                                                       Study type     Intervention                                                                                                                                                                                         Pts (n)                                        Thrombo- cytopenia (grades 3--4) (%)   Neutropenia (grades 3--4) (%)   Anemia (grades 3--4) (%)   Infection (grades 1--4) (%)                    Febrile neutropenia (%)   Human anti-mouse antibody (%)
  ------------------------------------------------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------------- ------------------------------- -------------------------- ---------------------------------------------- ------------------------- -------------------------------
  *Relapsed or refractory to chemotherapy without rituximab*                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Press *et al.,* 1993[@b8-co16-5-32]                                            Single-arm     ^131^[itb]{.smallcaps} phase [i]{.smallcaps} \[total body dose: 10--31 Gy (dose escalation)\]                                                                                                        43[a](#tfn17-co16-5-32){ref-type="table-fn"}   [nr]{.smallcaps}                       [nr]{.smallcaps}                [nr]{.smallcaps}           21                                             [nr]{.smallcaps}          7
   Press *et al.,* 1995[@b11-co16-5-32]                                           Single-arm     ^131^[itb]{.smallcaps} (total body dose: 27 Gy)                                                                                                                                                      21[b](#tfn18-co16-5-32){ref-type="table-fn"}   [nr]{.smallcaps}                       [nr]{.smallcaps}                [nr]{.smallcaps}           38[c](#tfn19-co16-5-32){ref-type="table-fn"}   [nr]{.smallcaps}          19
   Kaminski *et al.,* 2000[@b12-co16-5-32]                                        Single-arm     ^131^[itb]{.smallcaps} phase [i]{.smallcaps}/[ii]{.smallcaps} (phase [ii]{.smallcaps} total body dose: 75 cGy)                                                                                       59                                             40                                     55                              10                         22                                             [nr]{.smallcaps}          17
   Vose *et al.,* 2000[@b19-co16-5-32]                                            Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets ≤ 149,000/mm^3^)                                                                                                                47                                             [nr]{.smallcaps}                       11 (grade 4)                    [nr]{.smallcaps}           24                                             [nr]{.smallcaps}          2
   Kaminski *et al.,* 2001[@b5-co16-5-32]                                         Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                               60                                             2 (grade 4)                            18 (grade 4)                    0 (grade 4)                25                                             2                         8
   Davis *et al.,* 2003[@b22-co16-5-32] (abstract)                                *Randomized*   ^131^[itb]{.smallcaps} (total body dose: [nr]{.smallcaps})                                                                                                                                           42                                             12 (grade 4)                           17 (grade 4)                    5 (grade 4)                [nr]{.smallcaps}                               [nr]{.smallcaps}          27
                                                                                                 Unlabelled tositumomab                                                                                                                                                                               36                                             0 (grade 4)                            3 (grade 4)                     0 (grade 4)                [nr]{.smallcaps}                               [nr]{.smallcaps}          19
   Davies *et al.,* 2004[@b28-co16-5-32]                                          Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets ≤ 149,000/mm [@b3-co16-5-32])                                                                                                   41[d](#tfn20-co16-5-32){ref-type="table-fn"}   32                                     45                              5                          15 (grade 3--4)                                5                         10
  *Relapsed or refractory to rituximab with or without chemotherapy*                                                                                                                                                                                                                                                                                                                                                                                                                                                            
   Horning *et al.,* 2005[@b34-co16-5-32]                                         Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                               40[e](#tfn21-co16-5-32){ref-type="table-fn"}   25                                     42                              10                         55                                             [nr]{.smallcaps}          0
   Nair *et al.,* 2005[@b39-co16-5-32] (abstract)                                 Single-arm     ^131^[itb]{.smallcaps} (total body dose: 75 cGy, 65 cGy if platelets \< 150,000/mm^3^)                                                                                                               11                                             18 (grade 4)                           [nr]{.smallcaps}                [nr]{.smallcaps}           [nr]{.smallcaps}                               [nr]{.smallcaps}          [nr]{.smallcaps}
  *^131^[itb]{.smallcaps}conditioning for autologous stem cell transplantation*                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Press *et al.,* 2000[@b17-co16-5-32]                                           Single-arm     ^131^[itb]{.smallcaps} \[total body dose: 20--27 cGy (dose escalation)\], followed by etoposide, plus cyclophosphamide, plus autologous stem cell transplantation                                    52                                             100                                    100 (grade 4)                   [nr]{.smallcaps}           71[f](#tfn22-co16-5-32){ref-type="table-fn"}   [nr]{.smallcaps}          13
   Vose *et al.,* 2005[@b40-co16-5-32]                                            Single-arm     ^131^[itb]{.smallcaps} \[total body dose: 30--75 cGy (dose escalation)\], followed by [beam]{.smallcaps} (carmustine, etoposide, cytarabine, melphalan), plus autologous stem cell transplantation   23                                             100                                    100 (grade 4)                   [nr]{.smallcaps}           52                                             \>90%                     35
  *^131^[itb]{.smallcaps}in alternative regimens*                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   Kaminski *et al.,* 2003[@b23-co16-5-32] (abstract)                             Single-arm     ^131^[itb]{.smallcaps} (total body dose: [nr]{.smallcaps})                                                                                                                                           32                                             38                                     44                              [nr]{.smallcaps}           50                                             3                         10
   Mones *et al.,* 2004[@b32-co16-5-32] (abstract)                                Single-arm     ^131^[itb]{.smallcaps} \[total body dose: 45 cGy (10 cGy dose escalation increments)\]                                                                                                               11                                             [nr]{.smallcaps}                       [nr]{.smallcaps}                [nr]{.smallcaps}           [nr]{.smallcaps}                               [nr]{.smallcaps}          [nr]{.smallcaps}

Twelve patients received a therapeutic dose of ^131^[itb]{.smallcaps}; the number of patients that received a dosimetric dose of ^131^[itb]{.smallcaps} was not reported.

Of 25 enrolled patients, 4 did not receive treatment and were not included in the final analysis.

Two patients had grade 3 or 4 infection, and one patient died from infection (grade 5).

Of 44 enrolled patients, 3 did not receive treatment and were not included in the final analysis.

Of 43 enrolled patients, 3 did not receive treatment and were not included in the final analysis.

Four patients had grade 3 or 4 infection.

Pts = patients; [nr]{.smallcaps}= not reported.

###### 

Single-arm trials of ^131^I--tositumomab (^131^[itb]{.smallcaps}) in patients with previously untreated non-Hodgkin lymphoma ([nhl]{.smallcaps}): study characteristics

  Reference                                            Patient characteristics                                                                            Intervention                                                                                                                                                                                                                                                Pts (*n*)[a](#tfn24-co16-5-32){ref-type="table-fn"}
  ---------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  Press *et al.,* 2003[@b25-co16-5-32]                 Previously untreated CD20+ stage [ii]{.smallcaps}--[iv]{.smallcaps} follicular [nhl]{.smallcaps}   [chop]{.smallcaps} (cyclophosphamide 750 mg/m^2^ day 1, plus doxorubicin 50 mg/m^2^ day 1, plus vincristine 1.4 mg/m^2^ day 1, plus prednisone 100 mg days 1--5) every 21 days for 6 cycles, followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)   90
  Zelenetz *et al.,* 2003[@b27-co16-5-32] (abstract)   Previously untreated mantle-cell lymphoma                                                          ^131^[itb]{.smallcaps} (total body dose: [nr]{.smallcaps}), followed 13--16 weeks later by [chop]{.smallcaps}[b](#tfn25-co16-5-32){ref-type="table-fn"}                                                                                                     13
  Leonard *et al.,* 2004[@b29-co16-5-32] (abstract)    Previously untreated advanced low-grade [nhl]{.smallcaps}                                          Fludarabine 25 mg/m^2^ daily for 5 days, every 5 weeks for 3 cycles, followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                                                                                           38
  Link *et al.,* 2004[@b31-co16-5-32] (abstract)       Previously untreated follicular [nhl]{.smallcaps}                                                  [cvp]{.smallcaps} (cyclophosphamide 400 mg/m^2^ days 1--5, plus vincristine 1.4 mg/m^2^ day 1, plus prednisone 100 mg/m^2^ days 1--5) every 21 days for 6 cycles, followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                              30
  Kaminski *et al.,* 2005[@b35-co16-5-32]              Previously untreated advanced-stage follicular [nhl]{.smallcaps}                                   ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                                                                                                                                                                            76

Number enrolled and eligible.

Standard [chop]{.smallcaps}, but with a cyclophosphamide dose of 1000 mg/m^2^.

Pts = patients; [nr]{.smallcaps}= not reported.

###### 

Single-arm trials of ^131^I--tositumomab (^131^[itb]{.smallcaps}) in patients with previously untreated non-Hodgkin lymphoma: response and survival

  Reference                                           Intervention                                                                                Pts                                            [or]{.smallcaps}   [cr]{.smallcaps}                      Median results (months) for                      
  --------------------------------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------ ------------------ ------------------ ----------------------------- ------------------ ------
  Press *et al.,* 2003[@b25-co16-5-32]                [chop]{.smallcaps} followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)             90                                             90                 67                 Not yet reached    [nr]{.smallcaps}              Not yet reached    27.6
  Zelenetz, 2003[@b27-co16-5-32] (abstract)           ^131^[itb]{.smallcaps} (total body dose: [nr]{.smallcaps}) followed by [chop]{.smallcaps}   12[b](#tfn28-co16-5-32){ref-type="table-fn"}   75                 75                 [nr]{.smallcaps}   Not yet reached               [nr]{.smallcaps}   11
  Leonard *et al.,* 2004[@b29-co16-5-32] (abstract)   Fludarabine, followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                   35[c](#tfn29-co16-5-32){ref-type="table-fn"}   100                83                 Not yet reached    [nr]{.smallcaps}              [nr]{.smallcaps}   52.8
  Link *et al.,* 2004[@b31-co16-5-32] (abstract)      [cvp]{.smallcaps} followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)              30                                             100                80                 Not yet reached    [nr]{.smallcaps}              [nr]{.smallcaps}   27.6
  Kaminski *et al.,* 2005[@b35-co16-5-32]             ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                            76                                             95                 75                 73.2               [nr]{.smallcaps}              Not yet reached    61.2

Number included in the analysis.

Of 13 enrolled patients, 1 did not receive treatment with ^131^[itb]{.smallcaps} and was not included in the analysis of the data.

Of 38 enrolled patients, 3 did not receive treatment with ^131^[itb]{.smallcaps} and were not included in the analysis of the data.

Pts = patients; [or]{.smallcaps}= complete response, unconfirmed complete response, and partial response; [cr]{.smallcaps}= complete response and unconfirmed complete response; [ttp]{.smallcaps}= time to progression; [os]{.smallcaps}= overall survival; [chop]{.smallcaps}= cyclophosphamide, doxorubicin, vincristine, prednisone; [nr]{.smallcaps}= not reported; [cvp]{.smallcaps}= cyclophosphamide, vincristine, and prednisone.

###### 

Single-arm trials of ^131^I--tositumomab (^131^[itb]{.smallcaps}) in patients with previously Untreated non-Hodgkin lymphoma: adverse events

  Reference                                            Intervention                                                                                                                          Pts (*n*)[a](#tfn31-co16-5-32){ref-type="table-fn"}   Thrombocytopenia (grades 3--4) (%)   Neutropenia (grades 3--4) (%)   Anemia (grades 3--4) (%)   Infection (grades 1--4) (%)   Febrile neutronpenia (%)   Human anti-mouse antibody (%)
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------ ------------------------------- -------------------------- ----------------------------- -------------------------- -------------------------------
  Press *et al.,* 2003[@b25-co16-5-32]                 [chop]{.smallcaps} followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                       82[b](#tfn32-co16-5-32){ref-type="table-fn"}          11                                   13                              2                          2 (grade 3)                   [nr]{.smallcaps}           [nr]{.smallcaps}
  Zelenetz *et al.,* 2003[@b27-co16-5-32] (abstract)   ^131^[itb]{.smallcaps} (total body dose: [nr]{.smallcaps}) followed by [chop]{.smallcaps}[a](#tfn31-co16-5-32){ref-type="table-fn"}   12[c](#tfn33-co16-5-32){ref-type="table-fn"}          [nr]{.smallcaps}                     [nr]{.smallcaps}                [nr]{.smallcaps}           [nr]{.smallcaps}              42                         16
  Leonard *et al.,* 2004[@b29-co16-5-32] (abstract)    Fludarabine followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                              35[d](#tfn34-co16-5-32){ref-type="table-fn"}          29 (grade 4)                         34 (grade 4)                    3 (grade 4)                [nr]{.smallcaps}              [nr]{.smallcaps}           6
  Link *et al.,* 2004[@b31-co16-5-32] (abstract)       [cvp]{.smallcaps} followed by ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                        30                                                    23 (grade 4)                         33 (grade 4)                    [nr]{.smallcaps}           [nr]{.smallcaps}              [nr]{.smallcaps}           0
  Kaminski *et al.,* 2005[@b35-co16-5-32]              ^131^[itb]{.smallcaps} (total body dose: 75 cGy)                                                                                      76                                                    17                                   34                              0                          [nr]{.smallcaps}              0                          63

Number included in analysis.

Of 90 enrolled patients, 9 were not evaluable for toxicity.

Of 13 enrolled patients, 1 did not receive treatment with ^131^[itb]{.smallcaps} and was not included in the analysis of the data.

Of 38 enrolled patients, 3 did not receive treatment with ^131^[itb]{.smallcaps} and were not included in the analysis of the data.

Pts = patients; [chop]{.smallcaps}= cyclophosphamide, doxorubicin, vincristine, prednisone; [nr]{.smallcaps}= not reported; [cvp]{.smallcaps}= cyclophosphamide, vincristine, and prednisone.

###### 

Ongoing comparative or phase [iii]{.smallcaps} trials

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protocol ID                                                                                                     Title and details of trial
  --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [swog]{.smallcaps} S0016\                                                                                       Phase [iii]{.smallcaps} Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone ([chop]{.smallcaps}) with Either Rituximab or Iodine ^131^I Tositumomab (Monoclonal Antibody Anti-B1) in Patients with Newly Diagnosed Follicular Non-Hodgkin's Lymphoma
  NCT00006721\                                                                                                    
  [calgb]{.smallcaps} 50102                                                                                       

  ***Outcomes:*** Progression-free survival, overall survival, response, toxicity                                 

  ***Projected accrual:*** 500 patients                                                                           

  ***Status:*** Study is ongoing, but not recruiting participants                                                 

  ***Notes:*** A [chop]{.smallcaps}-only arm closed to recruitment on December 15, 2002                           

  ***Summary last modified:*** April 14, 2009                                                                     

  ***Accessed:*** May 10, 2009                                                                                    

  ***Available at:***[www.clinicaltrials.gov/ct2/show/NCT00006721](www.clinicaltrials.gov/ct2/show/NCT00006721)   

  [bmt]{.smallcaps} CTN0401\                                                                                      Phase [iii]{.smallcaps} Rituxan/[beam]{.smallcaps} vs. Bexxar/[beam]{.smallcaps} with Autologous Hematopoietic Stem Cell Transplantation ([asct]{.smallcaps}) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  NCT00329030                                                                                                     

  ***Outcomes:*** Progression-free survival, overall survival, response, toxicity                                 

  ***Projected accrual:*** 224 patients                                                                           

  ***Status:*** Currently recruiting                                                                              

  ***Summary last modified:*** April 8, 2009                                                                      

  ***Accessed:*** May 10, 2009                                                                                    

  ***Available at:***[www.clinicaltrials.gov/ct2/show/NCT00329030](www.clinicaltrials.gov/ct2/show/NCT00329030)   

  CCBX001-053\                                                                                                    A Comparative Study of Iodine I-131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
  NCT00078676\                                                                                                    
  NCT00319332                                                                                                     

  ***Status:*** Withdrawn                                                                                         

  ***Summary last modified:*** January 24, 2007.                                                                  

  ***Accessed:*** May 10, 2009                                                                                    

  ***Available at:***[www.clinicaltrials.gov/ct2/show/NCT00319332](www.clinicaltrials.gov/ct2/show/NCT00319332)   

  CCBX001-049\                                                                                                    A Study of Rituximab Versus Iodine I-131 Tositumomab Therapy for Patients with Non-Hodgkin's Lymphoma
  NCT00078598\                                                                                                    
  NCT00268983                                                                                                     

  ***Outcomes:*** Response and safety                                                                             

  ***Projected accrual:*** 506 patients                                                                           

  ***Status:*** Terminated                                                                                        

  ***Summary last modified:*** November 8, 2005                                                                   

  ***Accessed:*** May 10, 2009                                                                                    

  ***Available at:***[www.clinicaltrials.gov/ct2/show/NCT00078598](www.clinicaltrials.gov/ct2/show/NCT00078598)   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: For a complete list of current Hematology Cancer Disease Site Group members, visit the Program in Evidence-Based Care section of the Cancer Care Ontario Web site: [www.cancercare.on.ca/cms/one.aspx?pageId=10277](www.cancercare.on.ca/cms/one.aspx?pageId=10277).
